The BTN1A1 Knockout AGS Polyclonal Cells product provides a heterogeneous population of AGS human gastric adenocarcinoma epithelial cells engineered by CRISPR/Cas9-mediated disruption of the BTN1A1 gene. This polyclonal knockout pool offers a loss-of-function model to investigate the role of the butyrophilin BTN1A1 protein in immune regulation within a gastric cancer context. Unlike single-cell-derived clones, the polyclonal format retains genetic variability, facilitating robust population-level analyses and minimizing clonal artifacts.
The parental AGS cell line is a widely used model in gastric cancer research, derived from a tumor resected from a patient who had received no prior antitumor therapy. AGS cells are epithelial in origin and exhibit characteristics of gastric adenocarcinoma, making them valuable for studying tumorigenesis, drug sensitivity, and Helicobacter pylori infection mechanisms. Their established use in cancer biology ensures broad compatibility with standard molecular and cellular assays.
BTN1A1 is a member of the butyrophilin family of immune regulators, known to inhibit T cell proliferation and cytokine production upon interaction with activated T cells. It is transcriptionally regulated by STAT3 and NF-??B in response to prolactin and interferon-??, and its downstream effects involve modulation of p38 MAPK and ERK1/2 phosphorylation, ultimately suppressing T cell activation markers such as CD69 and IL-2. BTN1A1 interacts with the TCR complex and the P2X7 receptor, and homodimerization is critical for its function. Disruption of BTN1A1 is therefore expected to relieve T cell inhibition and enhance anti-tumor immune responses, particularly through the TCR?CCD3?CZAP70?CLCK?CERK signaling axis.
In the AGS gastric adenocarcinoma background, BTN1A1 knockout presents a powerful model for dissecting immune evasion strategies employed by gastric tumors. By eliminating this inhibitory signal, the polyclonal knockout cells can be utilized to study how gastric cancer cells modulate T cell function and to evaluate the potential of targeting BTN1A1 as an immune checkpoint. The model is particularly relevant for gastric cancer immunotherapy research, where the interplay between tumor cells and the immune microenvironment is a critical determinant of therapeutic outcome.
This product is ideally suited for a range of applications, including co-culture experiments with activated T cells to assess proliferation, cytokine secretion (e.g., via ELISA or Luminex), and activation marker expression by flow cytometry. Additional assays such as Western blotting, RT-qPCR, and RNA-seq can validate BTN1A1 knockout and explore downstream signaling changes. The polyclonal cells may also be employed in cell viability, migration, and invasion assays, as well as in vivo xenograft models to study tumor growth and immune infiltration. For further information or to discuss custom applications, please contact Ascent Research.
